Five-year results are in for pembrolizumab

The PD-1 antibody 'confers sustained disease control over a long period of time' in advanced melanoma

Confirmation that pembrolizumab (Keytruda) is a more effective medication for advanced melanoma than ipilimumab (Yervoy) comes from a five-year follow-up of a clinical trial.


The original study (KEYNOTE-006) randomised patients to one of two regimens of the programmed cell-death-1 (PD-1) antibody, pembrolizumab or to ipilimumab (a cytotoxic T-lymphocyte-associated antigen-4 antibody).

It found that after two years of treatment, the 556 patients who received either two or three-weekly pembrolizumab 10mg/kg for two years had better outcomes